Enovis (NYSE:ENOV – Get Rating) released its quarterly earnings results on Thursday. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.50 by $0.09, Briefing.com reports. The firm had revenue of $395.12 million for the quarter, compared to analyst estimates of $400.23 million. Enovis had a return on equity of 6.35% and a net margin of 1.77%. Enovis’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.68 EPS.
Enovis Stock Up 2.2 %
Shares of ENOV traded up $1.25 during trading on Friday, reaching $58.42. The company’s stock had a trading volume of 293,534 shares, compared to its average volume of 479,573. The business’s fifty day moving average price is $58.82. Enovis has a twelve month low of $52.27 and a twelve month high of $164.01. The company has a market cap of $3.16 billion, a P/E ratio of 44.25, a price-to-earnings-growth ratio of 1.22 and a beta of 2.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.03 and a current ratio of 1.62.
Institutional Investors Weigh In On Enovis
An institutional investor recently bought a new position in Enovis stock. Neuberger Berman Group LLC purchased a new stake in shares of Enovis Co. (NYSE:ENOV – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 22,754 shares of the company’s stock, valued at approximately $905,000.
Wall Street Analysts Forecast Growth
Enovis Company Profile
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.